据报康希诺生物(06185.HK)正向欧洲国家洽售新冠疫苗
据《彭博通讯社》报道,康希诺生物(06185.HK)表示,正与欧洲一些国家洽售其新冠疫苗。倘欧洲采购康希诺的疫苗,将标志着中国制造新冠疫苗在全球推广的重大突破。
报告引述公司负责国际业务的高级副总裁Pierre Morgon称,三个欧盟成员国已接洽公司讨论潜在购买事宜。
康希诺生物周一(22日)表示,其新冠疫苗已经获得匈牙利国家药品与营业研究所(OGYEI)的紧急使用授权;这为该公司单针疫苗在当地使用铺平了道路。Morgon表示,正在考虑扩大监管足迹,而欧洲肯定在内。匈牙利正在给整个局势带来转折,因为它是一个欧洲国家
报告称,虽然在目前全球可用的12种疫苗中,有四种来自中国这世界第二大经济体;但其疫苗主要流向那些难以获取西方公司,如辉瑞(PFE.US)和阿斯利康(AZN.US)之疫苗的开发中国家。西方公司的疫苗绝大部分流向了美国和其他富裕国家。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.